Reported 8 months ago
Novo Nordisk and Eli Lilly are pushing for Medicare coverage of their weight loss drugs through avenues like the Treat and Reduce Obesity Act. Novo's Wegovy gained Medicare coverage due to its cardiovascular benefits, while Lilly seeks expanded approval for Zepbound to address sleep apnea. The bill faces challenges in Congress due to high costs, with companies looking to address concerns around coverage and affordability.
Source: YAHOO